IACS-010759抑制線粒體氧化磷酸化及誘導腫瘤細胞凋亡的機制
瀏覽次數(shù):336 發(fā)布日期:2026-2-6
來源:本站 僅供參考,謝絕轉(zhuǎn)載,否則責任自負
IACS-010759(AbMole,M14466)是一種高度選擇性的線粒體復合物I(mitochondrial complex I)小分子抑制劑,可抑制氧化磷酸化(OXPHOS),從而影響細胞的能量代謝。IACS-010759通過抑制ATP生成,誘導能量耗盡、活性氧(ROS)積累和代謝重編程,最終導致細胞增殖抑制和凋亡[1]。在細胞實驗中,IACS-010759(CAS No.:1807523-99-4)被用于評估其對細胞線粒體呼吸和凋亡的影響。IACS-010759在0.1-1 μM濃度下,能顯著抑制AML細胞系(MOLM-14和MV4-11細胞)的增殖和呼吸,其效果表現(xiàn)出劑量依賴性。類似地對于高風險神經(jīng)母細胞瘤細胞,IACS-010759(IACS-10759)在低濃度(如0.5-5 μM)下即可抑制細胞增殖,并誘導凋亡,同時降低線粒體氧化磷酸化的活性[2]。 IACS-010759(1-10 μM)能有效抑制OXPHOS,逆轉(zhuǎn)抗雄激素處理(如Enzalutamide,MDV3100 )誘導的代謝轉(zhuǎn)換和腫瘤耐受[3]。
在動物實驗中,IACS-010759主要通過口服或腹腔注射給藥,評估其在動物體內(nèi)的抗腫瘤活性或研究線粒體呼吸。在黑色素瘤模型中,IACS-010759的給藥劑量為1-3 mg/kg[2]。IACS-010759在AML異種移植小鼠中,單藥處理(劑量1-5 mg/kg)即可顯著抑制腫瘤增殖,通過與Venetoclax(ABT-199) 聯(lián)合可增強小鼠的生存期(小鼠存活時間延長)[4]?傮w而言,在動物實驗中,IACS-010759(IACS-10759)在多種模型中表現(xiàn)出強效抗腫瘤活性,尤其在AML、腦癌、黑色素瘤等OXPHOS依賴型腫瘤中。IACS-010759在細胞實驗中多以DMSO作為母液進行溶解,在動物實驗中可采用0.5%甲基纖維素(Methyl cellulose)作為溶劑,并通過灌胃的形式進行給藥[5]。
參考文獻及鳴謝
[1] Pujalte-Martin, M.; Belaid, A.; Bost, S.; et al. Targeting cancer and immune cell metabolism with the complex I inhibitors metformin and IACS-010759.
Molecular oncology 2024,
18 (7), 1719-1738.
[2] Anderson, N. M.; Qin, X.; Finan, J. M.; et al. Metabolic Enzyme DLST Promotes Tumor Aggression and Reveals a Vulnerability to OXPHOS Inhibition in High-Risk Neuroblastoma.
Cancer research 2021,
81 (17), 4417-4430.
[3] Baumgartner, V.; Schaer, D.; Moch, H.; et al. Mitochondrial Elongation and ROS-Mediated Apoptosis in Prostate Cancer Cells under Therapy with Apalutamide and Complex I Inhibitor.
International journal of molecular sciences 2024,
25 (13).
[4] Liu, F.; Kalpage, H. A.; Wang, D.; et al. Cotargeting of Mitochondrial Complex I and Bcl-2 Shows Antileukemic Activity against Acute Myeloid Leukemia Cells Reliant on Oxidative Phosphorylation.
Cancers 2020,
12 (9).
[5] Aisu, Y.; Oshima, N.; Hyodo, F.; et al. Dual inhibition of oxidative phosphorylation and glycolysis exerts a synergistic antitumor effect on colorectal and gastric cancer by creating energy depletion and preventing metabolic switch.
PloS one 2024,
19 (12), e0309700.